Literature DB >> 31796915

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Anne Sophie Kubasch1,2,3, Freya Schulze2,3,4, Aristoteles Giagounidis2,3,5, Katharina S Götze2,3,6, Jan Krönke2,3,7, Katja Sockel2,3,4, Jan Moritz Middeke2,3,4, Fatiha Chermat3,8, Silke Gloaguen2,3, Martin Puttrich3,9, Carmen Weigt3,9, Doreen William10,11, Pierre Fenaux3,8,12, Richard F Schlenk3,11,13, Christian Thiede3,4, Sebastian Stasik3,4, Anna Mies3,4, Lionel Adès3,8,12, Uta Oelschlägel2,3,4, Uwe Platzbecker14,15,16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31796915      PMCID： PMC7214242          DOI： 10.1038/s41375-019-0645-z

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  Treatment of MDS.

Authors:  Uwe Platzbecker
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

3.  Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.

Authors:  Rami S Komrokji
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

4.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Erwin M Lee; Hayley S Ramshaw; Samantha J Busfield; Armando G Peoppl; Lucy Wilkinson; Mark A Guthridge; Daniel Thomas; Emma F Barry; Andrew Boyd; David P Gearing; Gino Vairo; Angel F Lopez; John E Dick; Richard B Lock
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

5.  Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.

Authors:  Michaela Graf; Karin Hecht; Susanne Reif; Renate Pelka-Fleischer; Karin Pfister; Helga Schmetzer
Journal:  Eur J Haematol       Date:  2004-02       Impact factor: 2.997

6.  Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Authors:  Pau Montesinos; Gail J Roboz; Claude-Eric Bulabois; Marion Subklewe; Uwe Platzbecker; Yishai Ofran; Cristina Papayannidis; Agnieszka Wierzbowska; Ho Jin Shin; Vadim Doronin; Stefan Deneberg; Su-Peng Yeh; Mehmet Ali Ozcan; Steven Knapper; Jorge Cortes; Daniel A Pollyea; Gert Ossenkoppele; Sergio Giralt; Hartmut Döhner; Michael Heuser; Liang Xiu; Indrajeet Singh; Fei Huang; Julie S Larsen; Andrew H Wei
Journal:  Leukemia       Date:  2020-03-16       Impact factor: 11.528

7.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Authors:  Pearlie K Epling-Burnette; Fanqi Bai; Jeffrey S Painter; Dana E Rollison; Helmut R Salih; Matthias Krusch; Jianxiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn Moscinski; Sheng Wei; Julie Y Djeu; Alan F List
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

8.  CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Authors:  L H Xie; M Biondo; S J Busfield; A Arruda; X Yang; G Vairo; M D Minden
Journal:  Blood Cancer J       Date:  2017-06-02       Impact factor: 11.037

Review 9.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

Review 10.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244
View more
  16 in total

1.  Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  Márcio Tavares; Sérgio Chacim; José Mário Mariz
Journal:  Ann Hematol       Date:  2020-10-01       Impact factor: 3.673

Review 2.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

Review 3.  CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

Authors:  Salvatore Fiorenza; Cameron J Turtle
Journal:  BioDrugs       Date:  2021-04-07       Impact factor: 5.807

Review 4.  Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).

Authors:  Michael Mann; Andrew M Brunner
Journal:  Curr Probl Cancer       Date:  2021-12-26       Impact factor: 3.187

5.  Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.

Authors:  Ibrahim Aldoss; Mary Clark; Joo Y Song; Vinod Pullarkat
Journal:  Hum Vaccin Immunother       Date:  2020-07-21       Impact factor: 3.452

6.  Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.

Authors:  Pinar Ataca Atilla; Mary K McKenna; Norihiro Watanabe; Maksim Mamonkin; Malcolm K Brenner; Erden Atilla
Journal:  Cytotherapy       Date:  2021-12-23       Impact factor: 5.414

Review 7.  Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications.

Authors:  Nathaniel A Long; Upendarrao Golla; Arati Sharma; David F Claxton
Journal:  Stem Cell Rev Rep       Date:  2022-01-20       Impact factor: 6.692

Review 8.  Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Kah Keng Wong; Rosline Hassan; Nik Soriani Yaacob
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

9.  Structural and evolutionary exploration of the IL-3 family and its alpha subunit receptors.

Authors:  Jade Fogha; Jagadeesh Bayry; Julien Diharce; Alexandre G de Brevern
Journal:  Amino Acids       Date:  2021-07-01       Impact factor: 3.520

Review 10.  BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?

Authors:  Cecily Allen; Amer M Zeidan; Jan Philipp Bewersdorf
Journal:  Life (Basel)       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.